Skip to main content

Table 2 HPV genotype distribution according to histological diagnosis

From: Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study

HPV genotypea CIN3 Adenocarcinoma in situ Squamous cell carcinoma Adenocarcinoma Invasive cancers (Squamous cell and adenocarcinoma)
N = 702 N = 33 N = 24 N = 9 N = 33
  n, % (95 CI) n, %, (95 CIb) n, %, (95 CIb) n, %, (95 CIb) n, %, (95 CIb)
HPV 16 and/or 18 427, 60.8 (57.1–64.5) 24,  72.7 (54.5–86.7) 16, 66.7 (44.7–84.4) 8, 88.9 (51.8–99.7) 24, 72.7 (54.5–86.7)
HVP 16 positive 398, 56.7 (52.9–60.4) 18, 54.5 (36.4–71.9) 14, 58.3 (36.6–77.9) 5, 55.6 (21.2–86.3) 19, 57.6 (39.2–74.5)
HPV 18 positive 36, 5.1 (3.6–7.0) 7, 21.2 (9.0–38.9) 3, 12.5 (2.7–32.4) 4, 44.4 (13.7–78.8) 7, 21.2 (9.0–38.9)
Any type in nonavalent vaccinec 626, 89.2 (86.6–91.4) 29, 87.9 (71.8–96.6) 23, 95.8 (78.9–99.9) 9, 100.0 (66.4–100.0) 32, 97.0 (84.2–99.9)
Any other IARC oncogenic type not in nonavalent vaccinec 56, 8.0 (6.1–10.2) 1, 3.0 (0.1–15.8) 1, 4.2 (0.1–21.1) 0, 0.0 (0.0–33.6) 1, 3.0 (0.1–15.8)
Any type not classified as oncogenic by IARCd 18, 2.6 (1.5–4.0) 0, 0.0 (0.0–10.6) 0, 0.0 (0.0–14.2) 0, 0.0 (0.0–33.6) 0, 0.0 (0.0–10.6)
HPV negativee 4, 0.6 (1.2–1.5) 1, 3.0 (0.1–15.8) 0, 0.0 (0.0–14.2) 0, 0.0 (0.0–33.6) 0, 0.0  (0.0–10.6)
  1. Abbreviations: CI confidence interval, IARC International Agency for Research on Cancer
  2. aMultiple HPV genotypes may be present for one biopsy, so column totals are greater than the number of biopsies and percentages do not sum to 100%
  3. bA one-sided 97.5% confidence interval was calculated if there were zero observations
  4. cOncogenic HPV genotypes in the nonavalent vaccine: 16, 18, 31, 33, 45, 52, 58
  5. dHPV genotypes classified as oncogenic by IARC: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59
  6. eAfter retesting by WHO Global HPV Reference Laboratory